- Investing Ideas
- U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
Results
3
0 new
High return on equity, past performance and sound balance sheet.
3 companies
Rigel Pharmaceuticals
Market Cap: US$533.2m
A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
RIGL
US$29.19
7D
-8.6%
1Y
47.9%
Exelixis
Market Cap: US$12.5b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$49.65
7D
-2.8%
1Y
15.8%
Catalyst Pharmaceuticals
Market Cap: US$3.8b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$31.28
7D
0.4%
1Y
29.7%